lutetium has been researched along with Liver Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 9 (39.13) | 2.80 |
| Authors | Studies |
|---|---|
| Caliebe, A; Jüptner, M; Lützen, U; Marx, M; Osmonov, D; Wrenger, R; Zhao, Y; Zuhayra, M | 1 |
| Boegemann, M; Kessel, K; Köhler, M; Rahbar, K; Roll, W; Seifert, R; Stegger, L; Weckesser, M | 1 |
| Baum, RP; Kulkarni, HR; Singh, A; Zhang, J | 1 |
| Barentsz, MW; Braat, AJAT; Ebbers, SC; Lam, MGEH; Moelker, A; Stokkel, MPM | 1 |
| Fidelman, N | 1 |
| Martins, H; Moreira, AP; Silva, R; Soeiro, P | 1 |
| Clift, AK; Frilling, A | 1 |
| Boegemann, M; Herrmann, K; Kessel, K; Kleesiek, J; Rahbar, K; Schäfers, M; Seifert, R; Seitzer, K; Weckesser, M | 1 |
| Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M | 1 |
| Delpassand, ES; Hendifar, AE; Kittleson, MM; Tuli, R | 1 |
| Dash, A; Gamre, N; Kumar, S; Pandey, U; Shaikh, S; Subramanian, S | 1 |
| Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ | 1 |
| Abdülrezzak, Ü; Buyukkaya, F; Karaca, H; Kula, M; Tutuş, A | 1 |
| Ahmadzadehfar, H; Essler, M; Schlenkhoff, C; Sopora, C; Wei, X | 1 |
| Geramifar, P; Kamali Asl, A; Khazaee Moghadam, M; Zaidi, H | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Sarma, HD; Venkatesh, M | 1 |
| Bleichrodt, R; Boerman, O; de Jong, G; Franssen, G; Hendriks, T; Oyen, W | 1 |
| Bleichrodt, RP; Boerman, OC; de Jong, GM; Eek, A; Hendriks, T; Nagtegaal, ID; Oyen, WJ | 1 |
| Kamali-Asl, A; Mohagheghpoor, E; Poorbaygi, H; Reza Aghamiri, SM; Sheibani, S | 1 |
| Baum, RP; Hommann, M; Kaemmerer, D; Prasad, V; Todorović-Tirnanić, M | 1 |
| Baechler, S; Boubaker, A; Dieudonné, A; Gardin, I; Hobbs, RF; Le Guludec, D; Lebtahi, R; Maurel, F; Sgouros, G; Wahl, RL | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E | 1 |
| Baum, RP; Müller, D; Senftleben, S; Wehrmann, C; Zachert, C | 1 |
2 trial(s) available for lutetium and Liver Neoplasms
| Article | Year |
|---|---|
Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Coordination Complexes; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver; Liver Neoplasms; Lutetium; Male; Multicenter Studies as Topic; Neuroendocrine Tumors; Octreotide; Radioisotopes; Randomized Controlled Trials as Topic; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome | 2020 |
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
21 other study(ies) available for lutetium and Liver Neoplasms
| Article | Year |
|---|---|
Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies | 2022 |
Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2020 |
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
Topics: Adult; Female; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals | 2020 |
Holmium-166 radioembolisation after peptide receptor radionuclide therapy: much needed data to help inform future research.
Topics: Holmium; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide | 2020 |
Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Humans; Liver Neoplasms; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Receptors, Peptide; Remission Induction | 2020 |
Combining radiolabelled therapies for neuroendocrine neoplasms.
Topics: Holmium; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Radioisotopes | 2020 |
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving
Topics: Aged; Aged, 80 and over; Antigens, Surface; Biomarkers, Tumor; Chemoradiotherapy; Dipeptides; Follow-Up Studies; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Liver; Liver Neoplasms; Lutetium; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Tolerance; Radiopharmaceuticals; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2020 |
Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
Topics: Cardiotoxicity; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide | 2018 |
Synthesis and Preliminary Biological Evaluation of
Topics: Animals; Carcinoma, Hepatocellular; Hydroxamic Acids; Liver Neoplasms; Lutetium; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar | 2019 |
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate | 2013 |
PET/CT and Bremsstrahlung Imaging After 90Y DOTANOC Therapy for Rectal Net With Liver Metastases.
Topics: Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2015 |
Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Topics: Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2016 |
Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study.
Topics: Algorithms; Bone Neoplasms; Computer Simulation; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Monte Carlo Method; Organ Specificity; Phosphorus Radioisotopes; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Planning, Computer-Assisted; Water; Yttrium Radioisotopes | 2016 |
Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer.
Topics: Animals; Biocompatible Materials; Drug Carriers; Drug Stability; Durapatite; Image Processing, Computer-Assisted; Isotope Labeling; Liver Neoplasms; Lutetium; Nanoparticles; Particle Size; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Whole-Body Counting; X-Ray Diffraction | 2008 |
Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Catheter Ablation; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Fluorodeoxyglucose F18; Liver Neoplasms; Lutetium; Male; Octreotide; Positron-Emission Tomography; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rats; Reproducibility of Results; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed; Triiodobenzoic Acids | 2011 |
Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Colorectal Neoplasms; Hepatectomy; Indium Radioisotopes; Liver Neoplasms; Lutetium; Male; Neoplasm Recurrence, Local; Radioimmunotherapy; Radioisotopes; Radiotherapy, Adjuvant; Rats; Rats, Inbred Strains; Survival Rate | 2011 |
Production of glass microspheres comprising 90Y and (177)Lu for treating of hepatic tumors with SPECT imaging capabilities.
Topics: Humans; Liver Neoplasms; Lutetium; Microspheres; Radioisotopes; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2011 |
Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Topics: Female; Humans; Intraoperative Period; Liver Neoplasms; Lutetium; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, X-Ray Computed | 2013 |
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Imaging, Three-Dimensional; Iodine Radioisotopes; Liver Neoplasms; Lutetium; Lymphoma, Non-Hodgkin; Microspheres; Models, Statistical; Monte Carlo Method; Neuroendocrine Tumors; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Dosage; Yttrium Radioisotopes | 2013 |
Model of metastatic growth valuable for radionuclide therapy.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Division; Computer Simulation; Dose-Response Relationship, Radiation; Humans; Liver Neoplasms; Lutetium; Models, Biological; Neoplasm Staging; Prognosis; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Relative Biological Effectiveness; Rhodium; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
Topics: Adult; Aged; Bone Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Radiotherapy; Radiotherapy Dosage; Receptors, Peptide; Tomography, X-Ray Computed | 2007 |